Company intelligence / Profile preview

Xunuo Pharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Xunuo Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule drugs. The company primarily targets oncology and metabolic diseases, leveraging its internal R&D platform to create highly selective therapies with optimized pharmacological profiles. Its lead candidate, XN-101, is a selective CDK4/6 inhibitor currently in Phase 2 clinical trials for the treatment of advanced breast cancer. Xunuo is backed by prominent venture capital firms and aims to deliver next-generation treatments for patients with significant unmet medical needs.

Therapeutic areas: Metabolic DisordersOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Xunuo Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xunuo Pharmaceutical.

Explore the full profile